Meeting Report

Optimizing Treatment of Chronic Lymphocytic Leukemia

Presented by Sandra E. Kurtin, PhD, ANP-C, AOCN®

From The University of Arizona Cancer Center, Tucson, Arizona


J Adv Pract Oncol 2021;12(3):325–328 | https://doi.org/10.6004/jadpro.2021.12.3.23 | © 2021 Harborside™


  

ABSTRACT

During JADPRO Live Virtual 2020, Sandra Kurtin, PhD, ANP-C, AOCN®, described personalization of the treatment of chronic lymphocytic leukemia (CLL) using molecular attributes of the disease, as well as patient characteristics. Dr. Kurtin discussed front-line treatment in previously untreated patients, treatment for relapsed or refractory CLL, and how to prevent, mitigate, and manage adverse events in order to optimize treatment. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2021 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.